Molecular genetics diagnostic company Mainz Biomed N.V. (NASDAQ:MYNZ) said on Tuesday that it has applied to the US Food and Drug Administration (FDA) for Breakthrough Device Designation for its next-generation colorectal cancer (CRC) screening test.
The test has demonstrated 97% sensitivity for cancer and 88% for advanced adenomas, with high specificity.
This designation, if granted, could expedite approval for the test that combines the Fecal Immunochemical Test (FIT) with mRNA biomarkers and AI analysis.
BD launches IVDR-certified self-collection solution to expand global access to HPV testing
Oticon launches Oticon Zeal, a discreet, fully featured in-the-ear hearing aid
Halozyme Therapeutics announces Q3 2025 release date
Samsung to invest USD110m in GRAIL and commercialise cancer detection test Galleri in Asia
Sebela's MIUDELLA Hormone-Free Copper IUS recognised in TIME's best inventions of 2025
Novocure announces presentation of new TTFields research at EANO and ESMO 2025 meetings
OSR Holdings to acquire Korean non-invasive glucose monitor developer Woori IO
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Polarean Imaging signs new supply agreementwith UVA Health for clinical Xenon MRI
Femasys partners with Kebomed to expand FemBloc permanent birth control in France and Benelux
Implantica receives positive FDA feedback on final RefluxStop PMA submission